Fig. 2From: Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstructionData on FEV1 and FVC. The data relates to the 10 subjects treated with LUM/IVA over 12 months. Individual data points are represented as well as the median and interquartile range. Analysis was done using one-way ANOVA with Dunnett’s multiple comparisons test. The overall ANOVA p value is given. The groups that are different from baseline (p < 0.05) are represented by *Back to article page